A single gene on chromosome 9 whose repeat, as it grows, reduces frataxin and leaves the mitochondrion without energy. An interactive journey through FXN, the GAA triplet, and the connection to the heart and cerebellum.
The entire journey of this page, summarized in steps.
Before diving into the genetics, it helps to understand the condition that the FXN gene explains.
Friedreich's ataxia is the most common inherited ataxia. It is autosomal recessive: it appears when both copies of the FXN gene, on chromosome 9, produce very little frataxin, a mitochondrial protein. Without enough frataxin, the mitochondrion fails and the nerve pathways and the heart are gradually damaged. It is a progressive disease that usually begins in childhood or adolescence.
In 1863, the German physician Nikolaus Friedreich first described this inherited ataxia, with involvement of gait, reflexes, and the heart. The molecular cause was revealed in 1996: the GAA triplet repeat expansion in intron 1 of the FXN gene, the starting point for the rest of this page.
The lack of frataxin affects several levels, which combine and vary from one person to another:
Progressive ataxia of gait and movement, loss of tendon reflexes, sensory and proprioceptive loss (damage to the dorsal root ganglia and spinocerebellar tracts), and dysarthria.
Hypertrophic cardiomyopathy and arrhythmias. It is the leading cause of death in the disease, which is why cardiology follow-up is essential.
Up to one third develop diabetes or glucose intolerance. Also scoliosis, foot deformity (pes cavus) and, over time, vision and hearing changes.
The most common: it begins before age 25, with large GAA expansions on both alleles. The earlier it appears, the faster the progression tends to be and the more likely cardiac involvement.
With smaller expansions, symptoms can begin after age 25 (LOFA) and even past 40 (vLOFA), with a slower course and sometimes preserved reflexes.
A small group has a GAA expansion on one allele and a point mutation on the other (compound heterozygotes). The picture may be somewhat different, but the mechanism — low frataxin — is the same.
It is not a static condition: there is a slow but continuous decline. Symptoms appear early and progress over the years, which is why follow-up is lifelong.
Unsteadiness when walking and running, clumsiness, and frequent falls in childhood or adolescence. This is usually when it is diagnosed.
The ataxia spreads to the arms and speech; scoliosis and, often, cardiac signs appear. Reflexes are lost.
Loss of independent walking (wheelchair), marked dysarthria, and possible diabetes. The heart requires close monitoring.
Rehabilitation, cardiac monitoring and, since 2023, omaveloxolone to slow progression. The approach is multidisciplinary.
In 2023 the first disease-specific medication was approved; together with rehabilitation and cardiac monitoring, it improves quality of life and slows progression.
Marketed as Skyclarys, it activates the Nrf2 antioxidant pathway and is the first approved drug for Friedreich's ataxia. It slows neurological decline; it is not a cure.
Physical therapy and speech therapy for gait and speech, management of cardiomyopathy and arrhythmias, diabetes management, and scoliosis surgery when needed.
Key for the family: because it is recessive, it identifies healthy carriers and provides guidance on transmission risk and reproductive options.
Educational content grounded in science (Friedreich's description, 1863; FXN gene, Campuzano et al. 1996; omaveloxolone approval, 2023; current clinical practice). It does not replace assessment by a healthcare professional.
The FXN gene, on chromosome 9, contains in its intron 1 a stretch where the GAA triplet repeats. This gene makes the protein frataxin, essential for assembling the iron-sulfur clusters inside the mitochondrion.
In most people there are 33 repeats or fewer. When the stretch expands (≥66, often 600–1200) on both copies, the chromatin compacts and the gene's transcription is reduced: little frataxin is made and Friedreich's ataxia appears.
The FXN gene is on chromosome 9, at band 9q21.11. Because it is an autosome (not a sex chromosome), two altered copies are needed for the disease to appear: its inheritance is recessive.
Unlike Huntington's (which makes a toxic protein), here the problem is the opposite: the GAA repeat compacts the chromatin and reduces transcription, so the cell is left with little frataxin. It is not due to the classic methylation that switches off other genes, but to heterochromatinization: the chromatin compacts and is read less well.
The number of GAA repeats determines how much frataxin is produced: from normal up to the pathogenic range that reduces transcription. Click each range to see what it means.
It shares its mechanism with other repeat expansion diseases. Click a row to see why the same idea produces such different diseases.
| Disease | Gene | Repeat | Threshold | Inheritance |
|---|---|---|---|---|
| Friedreich's ataxia view → | FXN | GAA | ≥ 66 | Autosomal recessive |
| Huntington's | HTT | CAG | ≥ 36–40 | Autosomal dominant |
| Fragile X | FMR1 | CGG | ≥ 200 | X-linked |
| Myotonic dystrophy type 1 | DMPK | CTG | ≥ 50 | Autosomal dominant |
| Spinocerebellar ataxia type 1 | ATXN1 | CAG | ≥ 39 | Autosomal dominant |
Friedreich's is special: the repeat does not create a toxic protein but instead reduces frataxin, and it is also the only recessive one in the group. Huntington's and Fragile X have their own atlas in this collection.
FXN doesn't act alone: its frataxin is part of the mitochondrial iron-sulfur machinery. Around it, other genes of that machinery and, for contrast, genes from other ataxias. Click a card to see the details.
FXN/frataxin at the center and, around it, the iron-sulfur machinery, the antioxidant defenses, and other ataxias. Hover over a node to identify it; click to see the details.
From Nikolaus Friedreich to the FXN gene and the first approved drug.
How the lack of frataxin damages the mitochondrion and, with it, the nerves and the heart.
Frataxin helps assemble the iron-sulfur clusters and handle mitochondrial iron. Without it, iron accumulates and generates oxidative stress. Compare the two states.
The FXN gene is on chromosome 9 (an autosome). Friedreich's ataxia is autosomal recessive: two altered copies are needed to develop the disease. Two healthy carriers (each with one altered copy and one healthy copy) can have an affected child, with no prior family history.
In each pregnancy of two carriers: 25% affected, 50% healthy carrier, and 25% non-carrier. It affects men and women equally. Carriers have no symptoms: they have a healthy copy of FXN that produces enough frataxin.
Adjust the size of the GAA expansion (of the shorter allele, which sets the pace) and you'll see the approximate level of remaining frataxin and how it relates to the age of onset. Illustrative model.
Indicative figures: the size of the shorter GAA allele correlates inversely with frataxin and with age of onset (larger expansions → less frataxin → earlier onset and more severe course). It is not an individual prediction.
The essentials about the genetics of Friedreich's ataxia:
The most important point: Friedreich's has a very well-defined molecular cause — low frataxin due to the GAA expansion — which makes it a clear therapeutic target. With omaveloxolone (2023) there is already a first approved drug, and research is exploring how to raise frataxin or reopen the gene.
It is a purely genetic disease. It is not caused by lifestyle or environment:
Rehabilitation and omaveloxolone improve the course, but the cause is always the same: the GAA expansion that reduces frataxin, inherited from two carrier parents.
Because of its so-clearly-defined cause, Friedreich's is one of the ataxias with the clearest therapeutic target: raising frataxin.
In 2023, omaveloxolone was approved, the first disease-specific medication for Friedreich's. It activates the Nrf2 antioxidant pathway and slows neurological decline: a milestone after decades without treatment.
The size of the shorter GAA expansion correlates with remaining frataxin, age of onset, and severity. Measuring it helps anticipate prognosis and design trials better.
In models, researchers have managed to decompact the chromatin of the FXN gene and increase its transcription. Proof of concept that the "silenced" gene can produce more frataxin again.
Delivering a functional copy of FXN with AAV vectors, especially to the heart and the nervous system, to restore frataxin at its source.
Molecules that boost production or stabilize existing frataxin, directly addressing the deficit that causes the disease.
Chelators targeting the accumulated mitochondrial iron and protectants against oxidative stress, to slow cellular damage.
Research is advancing fast and some of these results are preliminary: the dates and specific data may change as the trials mature.
The questions that come up most often when learning about Friedreich's ataxia.
Milestones and scientific sources this page is based on.
An educational synthesis page; it is not a primary clinical source. For medical decisions, consult professionals and the official resources of Friedreich's ataxia organizations.
Six questions to check what you take away. It grades itself: click an answer and you'll instantly see whether you're right, with the explanation.